Revolution Medicines, Inc.
NASDAQ:RVMD
59.1 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Revolution Medicines, Inc. |
Symbool | RVMD |
Munteenheid | USD |
Prijs | 59.1 |
Beurswaarde | 9,872,004,900 |
Dividendpercentage | 0% |
52-weken bereik | 18.79 - 60.53 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mark A. Goldsmith Ph.D. |
Website | https://www.revmed.com |
An error occurred while fetching data.
Over Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)